Increased sensitivity of gp210 autoantibody detection using a newly designed gp210 antigen

Jing Xu, Haoyi Zhang, Chan Wang, Peng Jiang, Chongxu Han, Yaping Dai, Fang Qiu, Yuhua Gong, Yuzhang Jiang, Ping Xu, Mingming Zhang, Luyao Zhang, Xingjuan Shi, Sufang Chen, Ye Tian, Michael F. Seldin, M. Eric Gershwin, Xiangdong Liu, Li Li

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The detection of autoantibody to glycoprotein 210 (gp210 Ab) against a 15 amino-acid peptide epitope by enzyme-linked immunosorbent assay (ELISA) has been widely used in the diagnosis of primary biliary cholangitis (PBC). However, this small peptide antigen presents spatial limitations for antibody access, which reduces the sensitivity of autoantibody detection. A recombinant gp210 antigen was constructed for increased sensitivity in antibody detection is described here. Methods: The gp210 C terminal 18 amino acid coding sequence was ligated to the modified C-terminal 108 amino acid coding sequence of human serum albumin (mHSA108) and produced as a recombinant gp210 antigen mHSA108-gp210-C18. Measurements of gp210 Ab using the gp210 C-terminal 25 amino acid peptide (gp210-C25) and mHSA108-gp210-C18 by in-house ELISA were compared. ELISAs with mHSA108-gp210-C18 and commercial INOVA kit for gp210 Ab detection were also compared in PBC patients and healthy controls. The correlation between the two assays was analyzed and their efficiency in diagnosing was compared. Results: Of 86 PBC samples, 35 (40.70%) and 44 (52.33%) positive samples were detected for anti-gp210 Ab using gp210-C25 and mHSA108-gp210-C18, respectively. Of 252 samples from PBC, 114 (45.24%) were positive for mHSA108-gp210-C18 ELISA whereas 94 (37.3%) for commercial ELISA (INOVA). All positive samples detected with commercial ELISA kit were also tested positive in mHSA108-gp210-C18 ELISA. Among 374 patients with other autoimmune diseases, anti-gp210 Ab were detected by mHSA108-gp210-C18 ELISA in 0.95% systemic lupus erythematosus (SLE) patients (2/210), 13.04% rheumatoid arthritis (RA) patients (13/97), and 1.47% of Sjögren's Syndrome (SS) patients (1/67). Conclusions: Compared to the gp210 peptide antigen, the sensitivity of the ELISA system using mHSA108-gp210-C18 antigen was improved. The novel gp210 antigen could be useful for screening patients known to be at increased risk of developing PBC.

Original languageEnglish (US)
Article number113211
JournalJournal of Immunological Methods
Volume501
DOIs
StatePublished - Feb 2022

Keywords

  • Enzyme-linked immunosorbent assay
  • Glycoprotein 210
  • Human serum albumin
  • Primary biliary cholangitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Increased sensitivity of gp210 autoantibody detection using a newly designed gp210 antigen'. Together they form a unique fingerprint.

Cite this